TERN - Terns Pharmaceuticals, Inc.
IEX Last Trade
5.855
0.025 0.427%
Share volume: 34,797
Last Updated: Thu 26 Dec 2024 08:30:14 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
1.30%
PREVIOUS CLOSE
CHG
CHG%
$5.83
0.03
0.43%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-2.19%
1 Month
-1.36%
3 Months
-34.46%
6 Months
-13.04%
1 Year
-11.99%
2 Year
-35.05%
Key data
Stock price
$5.86
DAY RANGE
$5.66 - $5.87
52 WEEK RANGE
$4.65 - $11.40
52 WEEK CHANGE
-$15.45
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/12/2024
Company detail
CEO: Senthil Sundaram
Region: US
Website: ternspharma.com
Employees: 40
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: ternspharma.com
Employees: 40
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Terns Pharmaceuticals, Inc. develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Recent news